AI Article Synopsis
- The study aimed to evaluate the effectiveness and safety of aerosolized iloprost in treating patients experiencing a pulmonary hypertensive crisis.
- Four patients with idiopathic pulmonary arterial hypertension received treatment, and results showed a significant decrease in systolic pulmonary arterial pressure (sPAP) and improved oxygen saturation levels.
- While the treatment was effective, some patients experienced adverse events like nausea and diarrhea, leading to treatment discontinuation in one case due to severe side effects.
Article Abstract
Objective: To summary the efficacy and safety of aerosolized iloprost in patients with pulmonary hypertensive crisis.
Methods: On the basis of conventional therapy, aerosolized iloprost (10 µg per time for 10 - 15 min in 2 hours interval, 8 times per day) was administered to four patients with idiopathic pulmonary arterial hypertension and pulmonary hypertensive crisis. Blood pressure, heart rate, systemic artery oxygen saturation, systolic pulmonary arterial pressure (sPAP) measured by echocardiography and the adverse events were analyzed.
Results: After aerosolized iloprost therapy, sPAP was significantly decreased and systemic artery oxygen saturation was improved. Adverse events (nausea, vomiting, diarrhea, dry cough) were observed in two patients, and the iloprost use was stopped in one patient due to severe vomiting and diarrhea.
Conclusion: Aerosolized iloprost could significantly reduce the sPAP and improve the systemic artery oxygen saturation in patients with pulmonary hypertension crisis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!